General Information


We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. There is an urgent medical need for therapies to treat a large number of patients suffering from viral diseases who currently have limited or no treatment options. To date, we have generated five innovative, allogeneic, off-the-shelf VST therapy candidates targeting 12 different devastating viruses, the most advanced of which has successfully completed a proof-of-concept trial across five viruses and is entering initial pivotal trials for the treatment of virus-associated hemorrhagic cystitis in the fourth quarter of 2020.

Employees: 21
Founded: 2014
Contact Information
Address 139 Main Street, Suite 500, Cambridge, MA 02142, US
Phone Number 617-433-2605
Web Address
View Prospectus: AlloVir
Financial Information
Market Cap $1065.4mil
Revenues $0 mil (last 12 months)
Net Income $-30.7 mil (last 12 months)
IPO Profile
Symbol ALVR
Exchange NASDAQ
Shares (millions): 16.3
Price range $17.00 - $17.00
Est. $ Volume $276.3 mil
Manager / Joint Managers Morgan Stanley/ J.P. Morgan/ SVB Leerink/ Piper Sandler
CO-Managers -
Expected To Trade: 7/30/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change